Nanomedicine, 2026 Aug 19:103008. PMID: 42617671 The authors introduce a novel intranasal protein nanoparticle influenza vaccine formulated with a semisynthetic saponin derivative, VSA-2, combined with MPLA, demonstrating potent and durable mucosal immunity and heterologous protection in mice. The plant-derived saponin derivative serves as an adjuvant that, when combined with MPLA, synergistically enhances immune activation.  The […]

Acta Biomater, 2026 Aug, 220:276-291. PMID: 42468600 This paper introduces a novel saponin-based nanoadjuvant, QS-NanoAlum, that leverages lysosomal disruption to induce immunogenic cell death (ICD) in tumors. Unlike traditional adjuvants that primarily enhance immune responses without direct tumor cell killing, QS-NanoAlum physically disrupts lysosomal membranes within tumor cells, causing their self-lysis and subsequent release of […]

Sci Rep, 2026 Aug 20, 16(1):26175. PMID: 42624960 Read this comprehensive comparison of the adjuvant effects of two advanced formulations, AS01 (containing QS-21 saponin and MPL-A) and AS03 (a squalene-based emulsion with tocopherol), against a traditional alum adjuvant in enhancing immune responses to GMP-grade H5N1 influenza vaccine in guinea pigs. It highlights the superior immunogenicity […]

Nature, 2026 Aug, 656(8128):723-733. PMID: 42380658 Building upon the design of germline-targeted Env immunogens that effectively prime V2 apex bnAb precursors (see previous paper from Marchitto et al), subsequent studies have demonstrated that sequential, lineage-based immunization strategies can further promote the maturation of these precursors into broadly neutralizing antibodies with high potency and breadth. Together, […]

Nature, 2026 Aug, 656(8128):712-722. PMID: 42380659 This Nature paper presents a significant advance in HIV vaccine design by demonstrating that germline-targeted Env immunogens can rapidly prime and induce broadly neutralizing V2 apex antibodies in macaques, including against challenging viruses with glycans at residue Asn130. The innovative aspect lies in the rationally designed immunogens, which include […]

Drug Saf, 2026 Aug 1. PMID: 42541670 Are you interested in a comprehensive two-year post-marketing safety surveillance of the AS01E-adjuvanted RSVPreF3 vaccine? This paper employs the liposomal saponin-based AS01E adjuvant system, highlighting its real-world safety profile in adults aged 60 and older. Given the critical role of saponin-based adjuvants like AS01E in enhancing immunogenicity, especially […]

This paper highlights the synergistic potential of combining saponin-based ISCOM adjuvants with immune regulatory modulation, specifically transient depletion of CD25+ regulatory T cells, to enhance influenza vaccine responses in aged mice.  The study demonstrates that while ISCOMs alone significantly boost antibody titers and protection, their effectiveness is further amplified when paired with targeted CD25+ cell […]

This study evaluates the immunogenicity and protective efficacy of a recombinant H5 hemagglutinin (HA) nanoparticle vaccine adjuvanted with Matrix-M, administered either intranasally or intramuscularly, against a highly pathogenic clade 2.3.4.4b H5N1 influenza virus in mice.  The research demonstrates that both routes induce robust systemic and mucosal antibody responses, including neutralizing antibodies, and confer complete protection […]